[시장보고서]세계의 HbA1c 검사 기기 시장 규모, 점유율, 동향 분석 : 기기 유형별, 기술별, 최종 용도별, 지역별, 부문 예측(2024-2030년)

세계의 HbA1c 검사 기기 시장 규모, 점유율, 동향 분석 : 기기 유형별, 기술별, 최종 용도별, 지역별, 부문 예측(2024-2030년)

HbA1c Testing Devices Market Size, Share & Trends Analysis Report By Type of Device (Point-of-care (POC) Testing Devices, Laboratory-based Testing Devices), By Technology, By End-use, By Region, And Segment Forecasts, 2024 - 2030

상품코드 : 1493185

리서치사 : Grand View Research

발행일 : 2024년 05월

페이지 정보 : 영문 125 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 HbA1c 검사 기기 시장 규모는 2024-2030년 CAGR 6.48%로 성장하며, 2030년에는 31억 5,000만 달러에 달할 것으로 예측되고 있습니다.

세계의 HbA1c 검사 기기 시장은 당뇨병 유병률 증가와 정확하고 효율적인 모니터링 솔루션에 대한 수요에 힘입어 괄목할 만한 성장을 보이고 있으며, CDC에 따르면 2021년에는 전체 인구의 11.6%에 해당하는 3,840만 명의 미국인이 당뇨병을 앓고 있을 것으로 예상됩니다. 여기에는 200만 명의 1형 당뇨병 환자가 포함되며, 이 중 약 30만 4,000명이 소아 및 청소년입니다. 이 보고서는 또한 매년 120만 명의 미국인이 당뇨병 진단을 받고 있으며, 당뇨병 치료 및 관리에 대한 지속적인 필요성을 강조하고 있으며, HbA1c 검사는 장기적인 혈당 조절에 대한 귀중한 인사이트을 제공하여 의료 서비스 프로바이더가 환자의 치료 계획을 최적화할 수 있도록 돕습니다. 환자의 치료 계획을 최적화할 수 있도록 지원함으로써 당뇨병 관리에서 중요한 역할을 하고 있습니다.

혈당 관리의 중요성과 HbA1c 검사 기기는 정확한 모니터링 툴에 대한 수요 증가, 기술 혁신 촉진, 특히 중저소득 국가에서 시장 확대로 인해 시장 성장의 원동력이 되고 있습니다. 불충분한 통제는 합병증을 유발하고 환자의 삶의 질과 의료 비용에 영향을 미칩니다. 한 연구에 따르면 DCCT(Diabetes Control and Complications Trial)는 엄격한 혈당 조절이 장기적인 합병증을 감소시켜 집중 치료의 비용 효율성을 강조하는 것으로 나타났습니다. 중저소득국가(LMICs)에서는 진단이 늦게 이루어지기 때문에 혈당 조절과 환자 교육이 중요합니다. 따라서 입원 치료 및 합병증 치료에 비해 비용을 절감하기 위해 조기 진단, 체계적인 합병증 검사 및 적시에 치료 강화의 필요성이 증가하고 있습니다.

시장은 빠른 결과를 제공하고 적시에 개입 및 맞춤 치료 계획을 가능하게 하는 POC(Point-of-care) 검사 기기로 눈에 띄는 변화를 목격하고 있으며, POC 검사 기기는 환자가 HbA1c 수치를 간편하고 효과적으로 모니터링할 수 있도록 도와준다, 재택의료 현장에서 널리 보급되고 있습니다. 이러한 추세는 헬스케어 분야에서 환자 중심의 치료와 원격 모니터링 솔루션의 채택이 점점 더 중요해지고 있음을 반영합니다.

ARKRAY, Inc., Abbott Laboratories, Chek, Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories, Inc. Diagnostics, Tosoh Corporation과 같은 주요 시장 기업은 HbA1c 검사 기기의 기술 혁신의 최전선에 있습니다. 이들 기업은 HbA1c 검사 기기의 정확성, 속도 및 사용 편의성을 향상시키는 첨단 기술 개발에 지속적으로 집중하여 의료진과 환자의 진화하는 요구에 부응하고 있습니다. 예를 들어 2022년 8월 DxGen Corp.과 Precision Diabetes, Inc.는 파트너십을 맺고 HbA1c를 포함한 당뇨병 검사를 위한 자동 현장진단 분석기인 Epithod AutoDx를 출시했습니다.을 통해 병원이나 진료소 등의 환경에서 빠른 결과를 얻을 수 있으며, COVID-19에 따른 현장 검사 수요 증가에 대응할 수 있습니다.

HbA1c 검사 기기 시장 보고서 하이라이트

POC(Point-of-Care) 검사 기기는 HbA1c 검사 기기 분야에서 압도적인 점유율을 차지하고 있으며, 당뇨병 관리에서 정보에 입각한 의사결정에 필수적인 용도이기 때문에 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
면역 분석은 신속하고 간편한 측정 결과를 얻을 수 있으며, 기술 분야에서 우위를 점하고 있습니다.
병원 및 클리닉의 최종 사용 부문이 2023년 시장을 장악했는데, 이는 병원 및 클리닉에서 이러한 기기를 효과적으로 처리할 수 있는 첨단 기술과 인프라가 잘 갖추어져 있기 때문입니다.
북미가 HbA1c 검사 기기 산업에서 우위를 점한 것은 높은 수준의 의료 인프라, 대상 질환의 유병률 증가, 양호한 규제 환경 등의 요인에 기인합니다.

주요 시장 참여 기업에 의한 최근 동향과 영향 분석
기업/경쟁 분류
벤더 구도
- 주요 대리점·채널 파트너 리스트
- 주요 고객
- 주요 기업의 시장 점유율 분석, 2023년
- Bio-Rad Laboratories, Inc.
- Abbott
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- HUMAN
- Trinity Biotech
- Menarini Diagnostics srl
- SAKAE CO. LTD.
- Ceragem Medisys Inc
- SEKISUI MEDICAL CO., LTD.

KSA

영문 목차

영문목차

HbA1c Testing Devices Market Growth & Trends:

The global HbA1c testing devices market size is anticipated to reach USD 3.15 billion by 2030, growing at a CAGR of 6.48% from 2024 to 2030, according to a new report by Grand View Research, Inc. The global market for HbA1c testing devices is witnessing significant growth, driven by the rising prevalence of diabetes and the demand for accurate and efficient monitoring solutions. According to the CDC, in 2021, 38.4 million Americans, or 11.6% of the population, had diabetes. This includes 2 million Americans with type 1 diabetes, approximately 304,000 of whom are children and adolescents. The report also highlights that 1.2 million Americans are diagnosed with diabetes annually, underscoring the persistent need for diabetes care and management. HbA1c testing plays a crucial role in diabetes management by providing valuable insights into long-term blood sugar control and assisting healthcare providers in optimizing patient treatment plans.

The importance of glycemic control and HbA1c testing devices drive market growth by increasing demand for accurate monitoring tools, fostering innovation, and expanding market reach, particularly in low- and middle-income countries. Inadequate control leads to complications, impacting patients' quality of life and healthcare costs. According to a study, the Diabetes Control and Complications Trial (DCCT) shows that strict glucose control reduces long-term complications, highlighting the cost-effectiveness of intensive treatment. In low- and middle-income countries (LMICs), owing to late diagnosis, glycemic control and patient education become crucial. This, in turn, propels the need for early diagnosis, systematic complication screening, and timely treatment intensification to lower costs compared to inpatient care and treatment of complications.

The market is witnessing a notable shift towards Point-of-care (POC) testing devices, which offer rapid results, enabling timely interventions and personalized treatment plans. POC devices are gaining extensive popularity in homecare settings, enabling patients to monitor their HbA1c levels conveniently and effectively. This trend reflects the growing emphasis on patient-centric care and adoption of remote monitoring solutions in healthcare.

Key market players such as ARKRAY, Inc., Abbott Laboratories, Chek, Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories, Inc., Trivitron Healthcare, EKF Diagnostics, and Tosoh Corporation are at the forefront of innovation in HbA1c testing devices. These companies are constantly focusing on developing advanced technologies to enhance the accuracy, speed, and user-friendliness of HbA1c testing devices, catering to the evolving needs of healthcare professionals and patients. For instance, in August 2022 , DxGen Corp. and Precision Diabetes, Inc. partnered to launch Epithod AutoDx, an automatic point-of-care analyzer for diabetes tests, including HbA1c. With a user-friendly design, it enables rapid results in settings such as physician offices and clinics, addressing the growing demand for on-site testing amid the pandemic.

HbA1c Testing Devices Market Report Highlights:

Point-of-care (POC) testing devices dominated the HbA1c type of device segment and are anticipated to grow at the fastest CAGR over the forecast period owing to their vital use for informed decision-making in diabetes management.
Immunoassays dominated the technology segment attributed to rapid and simplified results associated with the technology.
The hospitals and clinics end-use segment dominated the market in 2023, which is attributed to the well-equipped advanced technology and infrastructure available in hospitals and clinics to handle these devices effectively.
North America dominated the HbA1c testing devices industry owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Type of Device
- 1.2.2. Technology
- 1.2.3. End-use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Type of device
- 2.2.2. Technology outlook
- 2.2.3. End-use outlook
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. HbA1c Testing Devices Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Increasing prevalence of diabetes
  - 3.2.1.2. Technological advancement
  - 3.2.1.3. Development of novel testing methodologies.
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High cost of devices
  - 3.2.2.2. Stringent regulatory policies
3.3. HbA1c Testing Devices Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape
- 3.3.3. Pricing Analysis
- 3.3.4. Volume Analysis (Laboratory-based Testing Devices)

Chapter 4. HbA1c Testing Devices Market: Type of Device Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global HbA1c Testing Devices Market Movement Analysis
4.3. Global HbA1c Testing Devices Market by Type of Device Outlook
4.4. Laboratory-based Testing Devices
- 4.4.1. Laboratory-based Testing Devices market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Point-of-care (POC) Testing Devices
- 4.5.1 Point-of-care (POC) testing devices market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. HbA1c Testing Devices Market: Technology Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global HbA1c Testing Devices Market Movement Analysis
5.3. Global HbA1c Testing Devices Market by Technology Outlook
5.4. Immunoassays
- 5.4.1. Immunoassays market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Chromatography
- 5.5.1. Chromatography market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Enzymatic Assays
- 5.6.1. Enzymatic Assays market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Boronate Affinity Chromatography
- 5.7.1. Boronate Affinity Chromatography market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. High-Performance Liquid Chromatography
- 5.8.1. High-Performance Liquid Chromatography market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Others
- 5.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. HbA1c Testing Devices Market: End-use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global HbA1c Testing Devices Market Movement Analysis
6.3. Global HbA1c Testing Devices Market by End-use Outlook
6.4. Hospitals & Clinics
- 6.4.1. Hospitals & Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Diagnostic Laboratories
- 6.5.1. Diagnostic laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Homecare Settings
- 6.6.1. Homecare Settings market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. HbA1c Testing Devices Market: Regional Estimates & Trend Analysis by Type of Device, Technology, and End-use

7.1. Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
- 7.3.1. U.S.
  - 7.3.1.1. Key country dynamics
  - 7.3.1.2. Regulatory framework/ reimbursement structure
  - 7.3.1.3. Competitive scenario
  - 7.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.3.2. Canada
  - 7.3.2.1. Key country dynamics
  - 7.3.2.2. Regulatory framework/ reimbursement structure
  - 7.3.2.3. Competitive scenario
  - 7.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Europe
- 7.4.1. UK
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Regulatory framework/ reimbursement structure
  - 7.4.1.3. Competitive scenario
  - 7.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.2. Germany
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework/ reimbursement structure
  - 7.4.2.3. Competitive scenario
  - 7.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.3. France
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework/ reimbursement structure
  - 7.4.3.3. Competitive scenario
  - 7.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.4. Italy
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Regulatory framework/ reimbursement structure
  - 7.4.4.3. Competitive scenario
  - 7.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.5. Spain
  - 7.4.5.1. Key country dynamics
  - 7.4.5.2. Regulatory framework/ reimbursement structure
  - 7.4.5.3. Competitive scenario
  - 7.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.6. Norway
  - 7.4.6.1. Key country dynamics
  - 7.4.6.2. Regulatory framework/ reimbursement structure
  - 7.4.6.3. Competitive scenario
  - 7.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Key country dynamics
  - 7.4.7.2. Regulatory framework/ reimbursement structure
  - 7.4.7.3. Competitive scenario
  - 7.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.8. Denmark
  - 7.4.8.1. Key country dynamics
  - 7.4.8.2. Regulatory framework/ reimbursement structure
  - 7.4.8.3. Competitive scenario
  - 7.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Asia Pacific
- 7.5.1. Japan
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Regulatory framework/ reimbursement structure
  - 7.5.1.3. Competitive scenario
  - 7.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.2. China
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/ reimbursement structure
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.3. India
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/ reimbursement structure
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.4. Australia
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/ reimbursement structure
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework/ reimbursement structure
  - 7.5.5.3. Competitive scenario
  - 7.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.6. Thailand
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Regulatory framework/ reimbursement structure
  - 7.5.6.3. Competitive scenario
  - 7.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Latin America
- 7.6.1. Brazil
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Regulatory framework/ reimbursement structure
  - 7.6.1.3. Competitive scenario
  - 7.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.2. Mexico
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/ reimbursement structure
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.3. Argentina
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Regulatory framework/ reimbursement structure
  - 7.6.3.3. Competitive scenario
  - 7.6.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. MEA
- 7.7.1. South Africa
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Regulatory framework/ reimbursement structure
  - 7.7.1.3. Competitive scenario
  - 7.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.2. Saudi Arabia
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/ reimbursement structure
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Regulatory framework/ reimbursement structure
  - 7.7.3.3. Competitive scenario
  - 7.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.4. Kuwait
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Regulatory framework/ reimbursement structure
  - 7.7.4.3. Competitive scenario
  - 7.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2023
- 8.3.4. Bio-Rad Laboratories, Inc.
  - 8.3.4.1. Company overview
  - 8.3.4.2. Financial performance
  - 8.3.4.3. Product benchmarking
  - 8.3.4.4. Strategic initiatives
- 8.3.5. Abbott
  - 8.3.5.1. Company overview
  - 8.3.5.2. Financial performance
  - 8.3.5.3. Product benchmarking
  - 8.3.5.4. Strategic initiatives
- 8.3.6. F. Hoffmann-La Roche Ltd
  - 8.3.6.1. Company overview
  - 8.3.6.2. Financial performance
  - 8.3.6.3. Product benchmarking
  - 8.3.6.4. Strategic initiatives
- 8.3.7. Siemens Healthineers AG
  - 8.3.7.1. Company overview
  - 8.3.7.2. Financial performance
  - 8.3.7.3. Product benchmarking
  - 8.3.7.4. Strategic initiatives
- 8.3.8. HUMAN
  - 8.3.8.1. Company overview
  - 8.3.8.2. Financial performance
  - 8.3.8.3. Product benchmarking
  - 8.3.8.4. Strategic initiatives
- 8.3.9. Trinity Biotech
  - 8.3.9.1. Company overview
  - 8.3.9.2. Financial performance
  - 8.3.9.3. Product benchmarking
  - 8.3.9.4. Strategic initiatives
- 8.3.10. Menarini Diagnostics s.r.l
  - 8.3.10.1. Company overview
  - 8.3.10.2. Financial performance
  - 8.3.10.3. Product benchmarking
  - 8.3.10.4. Strategic initiatives
- 8.3.11. SAKAE CO. LTD.
  - 8.3.11.1. Company overview
  - 8.3.11.2. Financial performance
  - 8.3.11.3. Product benchmarking
  - 8.3.11.4. Strategic initiatives
- 8.3.12. Ceragem Medisys Inc
  - 8.3.12.1. Company overview
  - 8.3.12.2. Financial performance
  - 8.3.12.3. Product benchmarking
  - 8.3.12.4. Strategic initiatives
- 8.3.13. SEKISUI MEDICAL CO., LTD.
  - 8.3.13.1. Company overview
  - 8.3.13.2. Financial performance
  - 8.3.13.3. Product benchmarking
  - 8.3.13.4. Strategic initiatives

한글목차

HbA1c 검사 기기 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 HbA1c 검사 기기 시장 변수, 동향, 범위

제4장 HbA1c 검사 기기 시장 : 기기 유형 추정·동향 분석

제5장 HbA1c 검사 기기 시장 : 기술 추정·동향 분석

제6장 HbA1c 검사 기기 시장 : 최종 용도 추정·동향 분석

제7장 HbA1c 검사 기기 시장 : 지역 추정·동향 분석 - 기기 유형별, 기술별, 최종 용도별

제8장 경쟁 구도